Therefore, combination of targeting both mTOR signaling and Mnk/eIF4E pathway to enhance mTOR-targeted cancer therapy might be an innovation therapeutic strategy for NSCLC patients. The gene discussed is ATP7A; the disease is non-small cell lung carcinoma.